Wambeke David J.
Wambeke David J., CBO, reported an open-market or private purchase at NEUROONE MEDICAL TECHNOLOGIES Corp involving 33333.000000 shares for an estimated $66999.33. Reported holdings after the transaction were 199999.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Aug 27, 2026
- Filing date
- Sep 08, 2026
How reported position traded is calculated
Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 166,666 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingNMTC price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Buy Code P
- Identifier
- 0001971798-26-000005 Common Stock
- Transaction date
- Aug 27, 2026 Filed Sep 08, 2026, 12:31 PM · 12d delay
- Shares
- 33,333 sh $2.01 per share
- Estimated value
- $66.9k Computed from shares × price
- Holdings after
- 199,999 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+12 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- open_market_purchase+12 points
transaction_code = P
Code P is a discretionary open-market purchase. - direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - delayed_filing-6 points
reporting_delay_days = 12
Filing delay exceeds the configured threshold.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Business Officer
- F1
The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staf…
- F2
25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.
0 other transactions
0 recent txs